A detailed history of Capital International, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Capital International, Inc. holds 614,875 shares of BMY stock, worth $35.3 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares
614,875
Previous 628,870 2.23%
Holding current value
$35.3 Million
Previous $26.1 Million 21.84%
% of portfolio
0.42%
Previous 0.36%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $555,041 - $724,241
-13,995 Reduced 2.23%
614,875 $31.8 Million
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $11.6 Million - $15.2 Million
-287,254 Reduced 31.36%
628,870 $26.1 Million
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $5.02 Million - $5.69 Million
104,666 Added 12.9%
916,124 $49.7 Million
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $4.96 Million - $5.92 Million
102,374 Added 14.44%
811,458 $41.6 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $896,947 - $1 Million
-15,494 Reduced 2.14%
709,084 $41.2 Million
Q2 2023

Aug 11, 2023

BUY
$63.71 - $70.74 $10.3 Million - $11.4 Million
160,981 Added 28.56%
724,578 $46.3 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $6.89 Million - $7.81 Million
104,853 Added 22.86%
563,597 $39.1 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $2.17 Million - $2.57 Million
-31,669 Reduced 6.46%
458,744 $33 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $29,849 - $17.6 Million
-229,609 Reduced 31.89%
490,413 $34.9 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $1.3 Million - $1.44 Million
-17,962 Reduced 2.43%
720,022 $55.4 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $45.4 Million - $54.4 Million
737,984 New
737,984 $53.9 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Capital International, Inc. Portfolio

Follow Capital International, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.